Helping to improve your quality of life.

Ampio Pharmaceuticals is a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options. We are developing compounds that serve significant medical needs in osteoarthritis, diabetic macular edema, and other prevalent, inflammatory diseases through an innovative discovery and development platform.

Pharmaceutical Product Pipeline

Ampio has advanced its lead development assets into late-stage, pivotal clinical trials in the US.

Learn More About:

Osteoarthritis of the Knee

Ampio is developing Ampion™ for the treatment of osteoarthritis of the knee.


Diabetic Macular Edema

Ampio is developing Optina™ for the treatment of Diabetic Macular Edema.

AMPE Stock Quote - delayed
Last Change
AMPE 5.44

Ampio News

04/10/2014 | Press Release

Ampio Pharmaceuticals’ Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane™ in Canada and Other Territories to Broaden its International Footprint

04/09/2014 | Press Release

Results from the 20 weeks extension of the AmpionTM SPRING study to be presented at the Western Orthopedic Association Conference

04/02/2014 | Press Release

Luoxis Obtains CE Marking for RedoxSYS Diagnostic System

» See all Ampio news